This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
CARD Trial
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
Advanced Bladder Cancer
JAVELIN Bladder 100 Trial
Centers of Excellence
Urologic Oncology
Left Group
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Kidney Cancer Today
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Education
Covid-19
Urologic Oncology
Prostate Cancer
nmCRPC
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Pelvic Health & Reconstruction
Endourology
Testicular Cancer
Clinical Trials
From the Editor
Search Clinical Trials
Transformative Trials
DORA - PCCTC
IRONMAN - PCCTC
PROMISE - PCCTC
SPLASH Trial
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
BCANTT 2022
EAU 2022
See All
See All Conference Coverage
PCF
UroToday Home
Conference Highlights
ASCO GU 2020
ASCO GU 2020
Prostate Cancer
Kidney Cancer
Bladder Cancer
Penile, Urethral, Testicular, and Adrenal Cancers
Press Releases
ASCO GU 2020 Bladder Cancer
Viewing 1-20 of 46 articles
ASCO GU 2020: Results from BLASST-1 - Nivolumab, Gemcitabine, and Cisplatin in Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy.
ASCO GU 2020: Combining Chemotherapy with Novel Agents, Opportunities, and Challenges.
ASCO GU 2020: (NEO-BLADE) Phase II Randomized Placebo-Controlled Neoadjuvant Trial of Nintedanib or Placebo with Gemcitabine and Cisplatin in Locally Advanced Muscle Invasive Bladder Cancer
ASCO GU 2020: Results from ATLAS, a Phase 2, Open-Label Trial: Rucaparib for Recurrent, Locally Advanced or Metastatic Urothelial Carcinoma
ASCO GU 2020: The Efficacy of Two Cycles of Neoadjuvant Chemotherapy for Upper Tract Urothelial Carcinoma Patients.
ASCO GU 2020: Sequencing Chemotherapy and Surgery in Upper Tract Urothelial Cancers
ASCO GU 2020: Replacing TURBT with mpMRI for Staging MIBC: Pilot Data from the BladderPath study
ASCO GU 2020: Germline DNA Copy Number Polymorphism to Predict the Efficacy of BCG Therapy for Non-Muscle Invasive Bladder Cancer
ASCO GU 2020: Randomized Phase III trial for Treatment of Muscle-Invasive Urothelial Bladder Cancer: Preliminary Results of the GETUG/AFU V05 VESPER Trial on Toxicity and Pathological Responses
ASCO GU 2020: Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma - Preliminary Durability Results from Study EV-103
ASCO GU 2020: Risk Stratification and Management of High-Risk Muscle-Invasive Urothelial Carcinoma: Subtyping of High-risk Muscle Invasive Urothelial Carcinoma
ASCO GU 2020: Opportunities and Limitations of Genomics in Everyday Practice: Circulating Tumor DNA (ctDNA)
ASCO GU 2020: Practicing Beyond Clinical Trial Data: Real-World Challenges in Urothelial Carcinoma
ASCO GU 2020: Risk Stratification and Management of High-Risk Muscle-Invasive Urothelial Carcinoma: Adjuvant Options in High-Risk Disease After Primary Intervention
ASCO GU 2020: Circulating Tumor Cells: Opportunities in Muscle Invasive Bladder Cancer
ASCO GU 2020: Adjuvant Options in High-Risk Muscle Invasive Bladder Cancer After Primary Intervention
ASCO GU 2020: Medical Oncology Perspective - Best of Journals: Urothelial Carcinoma
ASCO GU 2020: Risk Stratification and Management of High-Risk Muscle Invasive Urothelial Carcinoma: Circulating Tumor DNA
ASCO GU 2020: Adjuvant Options in High-Risk Disease After Primary Intervention
ASCO GU 2020: Upper Tract Disease: Topical Therapy, Systemic Therapy
1
2
3
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free